Introduction
============

Osteoporosis is a chronic systemic skeletal disorder characterized by decreased bone mass and qualitative alterations in bone and is accompanied by an increased risk of fracture.[@b1-dddt-12-3929]--[@b3-dddt-12-3929] It is a common consequence of aging that affectŝ200 million individuals and causes 8.9 million fractures every year.[@b4-dddt-12-3929] In the USA and Europe, 30% of all postmenopausal women have osteoporosis.[@b5-dddt-12-3929] The diagnostic of osteoporosis by the World Health Organization (WHO) criteria is based on the measurement of bone mineral density (BMD), which is usually measured using densitometry applications such as dual X-ray photon absorptiometry.[@b2-dddt-12-3929],[@b6-dddt-12-3929] However, it is not sufficient only to do the densitometry as a diagnostic because many fragility fractures after osteoporosis occurs in the range of normal BMD values, so a clinical diagnostic should combine densitometric examination with clinical evaluations, laboratory tests, and related differential diagnoses.[@b1-dddt-12-3929],[@b2-dddt-12-3929] The National Osteoporosis Foundation suggested that treatment for osteoporosis should start with a non-pharmacologic approach, such as resistance and weight-bearing exercise.[@b6-dddt-12-3929],[@b7-dddt-12-3929] Bisphosphonates are typically the first-line pharmacologic agents for the treatment of patients with osteoporosis.[@b8-dddt-12-3929],[@b9-dddt-12-3929] However, osteonecrosis of the jaw is a known complication in a subset of patients receiving bisphosphonate treatment.[@b10-dddt-12-3929],[@b11-dddt-12-3929] Furthermore, a previous study showed that in MEPS, bisphosphonate use was increased predominantly in women (from 3.5% in 1996 to 16.6% in 2007) compared with men (2.3% in 2007), and women experienced the vast majority of subtrochanteric fractures.

Thiazide diuretics were the first tolerated efficient anti-hypertensive drugs and have been used as a part of treatment strategies in numerous clinical trials involving hypertension; they are considered unequivocally effective in the treatment of hypertensive patients.[@b12-dddt-12-3929],[@b13-dddt-12-3929] Furthermore, thiazides have been regarded as candidates for the prevention of postmenopausal bone loss for many years because of their ability to decrease urinary calcium excretion at the level of the renal tubules.[@b14-dddt-12-3929] Defects in the tubular excretion of calcium are one of the main causes of osteoporosis. In a previous study, thiazide diuretics were shown to slow the rate of bone loss in older adults.[@b15-dddt-12-3929] Furthermore, it has been demonstrated that thiazides have direct effects on osteoclasts and osteoblasts.[@b16-dddt-12-3929],[@b17-dddt-12-3929] However, there is insufficient evidence that thiazides have a sustained beneficial effect in preserving bone mass and preventing osteoporosis to date.

This systematic review and meta-analysis was conducted to determine whether thiazides are beneficial for preserving bone mass and have an effect on the prevention and treatment of osteoporosis. In this study, we analyzed the effect of thiazides on serum and urinary calcium levels and BMD.

Materials and methods
=====================

Search strategy
---------------

We searched PubMed, the Cochrane Library, and Embase in June 2018 for studies using the following combination of terms: "Thiazides," "Benzothiadiazines," "Bendroflu-methiazide," "Chlorothiazide," "Cyclopenthiazide," "Diazoxide," "Hydroflumethiazide," "Methyclothiazide," and "Polythiazidein" in combination with "Osteoporosis," "Osteoporoses," "Osteoporosis, Post-Traumatic," "Osteoporosis, Post Traumatic," "Post-Traumatic Osteoporoses," "Post-Traumatic Osteoporosis," "Osteoporosis, Senile," "Osteoporoses, Senile," "Senile Osteoporoses," "Senile Osteoporosis," "Osteoporosis, Involutional," "Osteoporosis, Age-Related," "Osteoporosis, Age Related," "Bone Loss, Age-Related," "Age-Related Bone Loss," "Age-Related Bone Losses," "Bone Loss, Age Related," "Bone Losses, Age-Related," "Age-Related Osteoporosis," "Age Related Osteoporosis," "Age-Related Osteoporoses," and "Osteopo-roses, Age-Related," and only English papers were included. Furthermore, the articles in reference lists of the related studies were also reviewed. Two independent reviewers examined the titles and abstracts for eligibility, and if we cannot judge whether the articles are eligible based on the titles and abstracts, the full-text article was obtained and reviewed for final inclusion. Moreover, we only included the complete original articles.

Study selection
---------------

The studies were selected according to the following inclusion criteria: 1) the studies were designed as randomized controlled trials (RCTs); 2) participants were adults with osteoporosis or the high-risk group of osteoporosis; 3) the thiazide intervention was compared with placebo control in the meantime -- patients in the control groups used placebo that did not influence bone anabolism. Furthermore, studies were excluded according to the following exclusion criteria: 1) participants had taken thiazides, unless patients had gone through a washout period; 2) the patients were allergic to thiazides formerly or currently; and 3) except for RCTs, other types of studies such as abstracts, review articles, and letters.

Data extraction and quality assessment
--------------------------------------

The following data with regard to thiazide intervention in patients with osteoporosis were extracted: 1) name of the first author, publication year; 2) participants' characteristics (gender, mean age); 3) type of intervention; 4) number of cases and participants; and 5) BMD, serum calcium, and urinary calcium from each included study. Moreover, the quality of the studies we selected was assessed according to the Cochrane risk of bias tool, including selection bias, performance bias, detection bias, attrition bias, and reporting bias.[@b18-dddt-12-3929] Each category included the following three levels: low risk, unclear risk, and high risk.

Statistical analysis
--------------------

The data syntheses were performed by Review Manager Software (RevMan version 5.2; The Cochrane Collaboration, Copenhagen, Denmark). Only outcomes addressed by at least two studies were analyzed. The meta-analysis was analyzed with a random effects model. Continuous outcomes were presented as standardized mean difference (SMD) and 95% CI. Study heterogeneity was measured using Cochran's Q statistic and I[@b2-dddt-12-3929] statistic, and it was regarded significant when *P*\<0.05 for the former and I[@b2-dddt-12-3929] \>50% for the latter.[@b19-dddt-12-3929],[@b20-dddt-12-3929]

Results
=======

Literature search
-----------------

A total of 33 potentially relevant studies as of June 2018 were identified, 12 of which were excluded because they were duplicate publications, were not RCTs, or included exposures or end points not related to our meta-analysis. After a full-text review of the remaining studies, five publications were included.[@b21-dddt-12-3929]--[@b25-dddt-12-3929] [Figure 1](#f1-dddt-12-3929){ref-type="fig"} shows the details of the screening process.

Study and patient characteristics
---------------------------------

The five eligible studies included 756 participants, including 614 women (81.2%) and 142 men (18.8%). Moreover, types of interventions included bendroflumethiazide and hydro-chlorothiazide. The total number of the included patients with active treatment and placebo treatment is 372 and 384, respectively. The duration of thiazide therapy ranged from 2 to 3 years. Overall mean age was 64.45±6.69 (mean ± SD) years. [Table 1](#t1-dddt-12-3929){ref-type="table"} shows the characteristics of the included studies in detail.

Quality of trials
-----------------

The quality of the five included RCTs was assessed using the Cochrane risk of bias tool, as described in [Figure 2](#f2-dddt-12-3929){ref-type="fig"} in detail. All the studies were judged to be at low risk of bias in terms of random sequence generation, allocation concealment, and blinding of participants and personnel. One trial was judged to be at high risk for incomplete outcome data and blinding of outcome assessment, while other trials (such as recruitment bias and contamination of the interventions) were at low risk. The rate of patients lost to follow-up was also assessed, and one trial indicated the presence of loss to follow-up, which was 3.44%.[@b22-dddt-12-3929] Disagreement was resolved by discussion among the authors.

Serum calcium
-------------

Four trials (543 patients) included an analysis of serum calcium after the intervention. The results showed that patients treated with thiazides had significantly higher calcium levels compared with patients in the control group (SMD 0.33, 95% CI \[0.16, 0.50\]; I[@b2-dddt-12-3929] of heterogeneity 0%; random effects model) ([Figure 3](#f3-dddt-12-3929){ref-type="fig"}).

Urinary calcium
---------------

Three trials (489 patients) included an analysis of urinary calcium after the intervention. The results showed that patients in the thiazide group showed significantly lower urinary calcium levels compared with the control groups (SMD −0.35, 95% CI \[−0.52, −0.17\]; I[@b2-dddt-12-3929] of heterogeneity 0%; random effects model) ([Figure 4](#f4-dddt-12-3929){ref-type="fig"}).

BMD
---

BMD data obtained using dual-energy X-ray absorptiometry were analyzed in two studies involving 398 patients (200 in the thiazide group and 198 in the control group).[@b22-dddt-12-3929],[@b24-dddt-12-3929] The results showed that patients treated with thiazides had no statistically significant difference in BMD compared with the control group (SMD 0.19, 95% CI \[−0.16, 0.54\]; I[@b2-dddt-12-3929] of heterogeneity 68%; random effects model) ([Figure 5](#f5-dddt-12-3929){ref-type="fig"}). Although significant heterogeneity was evident, sensitivity analysis was not performed due to the small number of trials. The significant heterogeneity could be attributed to the different methods of evaluation used in the trials.

Discussion
==========

Thiazides have been widely used as antihypertensive drugs with a tolerable efficiency.[@b26-dddt-12-3929] Previous studies have shown that thiazides may also affect bone metabolism and BMD.[@b27-dddt-12-3929],[@b28-dddt-12-3929] However, the effectiveness of thiazides in the treatment of osteoporosis has not been fully elucidated. The present meta-analysis summarized the results of the five included RCTs that assessed the effects of thiazides on the BMD and mineral metabolism in the elderly. The findings suggest that thiazides have some benefits for preserving bone mass and may be effective in the prevention and treatment of osteoporosis.

BMD in the thiazide group did not differ significantly from that in the control group. The quality of this evidence was assessed to be very low because only two RCTs provided BMD data.[@b22-dddt-12-3929],[@b24-dddt-12-3929] Therefore, insufficient data limited the quality of evidence. Four of the RCTs indicated that thiazides had a positive effect on BMD.[@b21-dddt-12-3929]--[@b24-dddt-12-3929] Thus, there is evidence to support the beneficial effects of thiazides on BMD, but this was not confirmed in this analysis. If we want to confirm that thiazides have beneficial effect on BMD, more high-quality RCTs are needed in the future.

Measurement of serum calcium should be one of the first-line investigations in patients with osteoporosis.[@b1-dddt-12-3929] Elevated serum calcium is associated with a wide range of adverse health outcomes including osteoporosis, and decreased urinary calcium excretion can lead to increased serum calcium levels. In the current meta-analysis, the results suggest that the use of thiazides could lead to a significant increase in serum calcium level compared with that in the control group. Furthermore, urinary calcium excretion has been shown to be low in many postmenopausal women and in the elderly because of impaired intestinal calcium absorption.[@b29-dddt-12-3929],[@b30-dddt-12-3929] Previous studies have reported that thiazides can reduce urinary calcium excretion by 25%--40%, potentially improving bone mass and reducing fracture risk, while intestinal calcium absorption keeps on persistently elevated.[@b31-dddt-12-3929]--[@b35-dddt-12-3929] In these results, urinary calcium excretion declined signifi-cantly in the thiazide group. There was no heterogeneity in these results, which could reach statistical significance in the current meta-analysis. To sum up, combining the results, the meta-analysis indicated that thiazides have the possible effect on the prevention and treatment of osteoporosis.

Certain limitations of this meta-analysis should be acknowledged. First, evidence of the benefit was limited because of the small number of RCTs. Second, not all the included studies provided all the data that we sought; for example, although two studies reported significant between-group differences in BMD, the data provided were not detailed. Thus, quality of the evidence was limited by insufficient data. Third, this meta-analysis included the only papers published in English language, and so trials published in other languages were systematically excluded. Fourth, over 81.2% (n=614) of the included subjects were females and only 18.8% (n=142) of the included subjects were males, so the results of this study are more applicable to females. Despite these limitations, this study supports the use of thiazides to increase serum calcium levels and decrease urinary calcium excretion in patients with osteoporosis.

Conclusion
==========

The results of this meta-analysis demonstrated that thiazides might play a role in preserving bone mass in patients with osteoporosis and have the possible effect on the prevention and treatment of osteoporosis. However, we must interpret the results cautiously because of some limitations, and future high-quality trials are needed to confirm these findings.
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###### 

Characteristics of the included studies

  Study                               Number of patients   Age, years   Sex    Calcium intake (mg/day)   Current smoker, n (%)   Alcohol, g/d   N~T~/N~C~   Intervention   Interventional time, years                                                                                                                  
  ----------------------------------- -------------------- ------------ ------ ------------------------- ----------------------- -------------- ----------- -------------- ---------------------------- ---------- ---------- --------- ------------------------------------------------- ---------------------------- ---
                                                                                                                                                                                                                                                                                                                       
  Transbøl et al[@b25-dddt-12-3929]   54                   50.12        2.66   0                         54                      --             --          --             --                           --         --         21/33     Bendroflumethiazide (5 mg/d), calcium (0.5 g/d)   Placebo, calcium (0.5 g/d)   2
  Reid et al[@b24-dddt-12-3929]       185                  63.00        5.50   0                         185                     960±490        1,040±490   6 (7)          5 (5)                        --         --         92/93     Hydrochlorothiazide (50 mg/d)                     Placebo                      2
  Lacroix et al[@b22-dddt-12-3929]    213                  67.69        4.70   77                        136                     1,071±619      1,189±653   9 (8)          9 (9)                        9.0±13.6   6.7±10.4   108/105   Hydrochlorothiazide (12.5 mg/d)                   Placebo                      3
  Bolland et al[@b21-dddt-12-3929]    122                  62.44        5.31   0                         122                     939±482        1,042±527   --             --                           --         --         57/65     Hydrochlorothiazide (50 mg/d)                     Placebo                      2
  Ott et al[@b23-dddt-12-3929]        182                  67.72        4.45   65                        117                     1,053±130      1,196±326   8 (9)          8 (9)                        --         --         94/88     Hydrochlorothiazide (12.5 mg/d)                   Placebo                      3

**Abbreviations:** G~C~, control group; G~T~, thiazides group; N~C~, number of patients in control group; N~T~, number of patients in thiazides group.
